Primary Sclerosing Cholangitis Market Growth, Demand and Forecast Till 2023 Explore By Global Players Allergan Plc., Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc.

Primary sclerosing cholangitis market report provides detailed information about various candidates that are presently in the preclinical and clinical trials by the manufacturers and research organizations. The drug segment will provide quick snapshot about the clinical phase of the study, study outcomes, estimated launch date, and the upcoming drug molecules. Moreover, the report entails information regarding the major events taking place in the global market, thereby gaining insights about drug approvals, merger agreements, and acquisitions undertaken by the manufacturing companies. Also, incidence and prevalence of PSC and its associated conditions at regional as well as global level are provided in the report, thereby indicating the total number of addressable patient pool in the respective regions and market opportunity for the same.

Ask For In-depth Sample Copy of This Report @ https://bit.ly/2EjNoOm

Market Dynamics

Major factors that are expected to augment growth of the primary sclerosing cholangitis market include increasing number of organizations focusing on clinical innovation and scientific progress on understanding the mechanisms and risk factors for primary sclerosing cholangitis (PSC). For instance, the International PSC study group (IPSCSG), founded in 2010, aims to coordinate PSC research projects between leading institutions worldwide, thereby allowing feasible translational research and advancing efficient research. Also, increasing number of clinical and preclinical trials conducted by the research universities and pharmaceuticals companies is expected to favor market growth over the forecast period.

Global Primary Sclerosing Cholangitis Market- Optimistic Regional Scenario:

Currently, over five products are in clinical trials Phase 2 and some of them have shown good results in Phase 2. For instance, ASEOP trial, testing Obeticholic acid (OCA) for primary sclerosing cholangitis, is being conducted by Intercept Pharmaceuticals, Inc. Also, Shire Plc. completed Phase 2 clinical trial for the drug candidate LUM001 in February, 2016. If these potential molecules pass through the advanced clinical trials phase (i.e. Phase 3) and secure regulatory approval, these would be among the first-to-get-approval for this disease.

Moreover, most of the patients are in developed economies such as Europe and North America where diagnosis percentage and affordability is generally higher compared to emerging economies in regions such as Asia Pacific, which would result in higher adoption rate of novel products with significantly high yearly cost (i.e. more than US$ 50,000 for orphan drugs). Due to the above mentioned factors, the global primary sclerosing cholangitis market is expected to reach US$ 140.4 Mn by 2023. However, withdrawal of potential therapeutic molecules from late-stage clinical trials have limited the availability of efficient treatment, thus compelling the patient pool to adopt alternative treatment therapies such as bile acid sequestrants, antibiotics, antihistamines, opioid antagonists, and ursodeoxycholic acid (UDCA).

Increasing incidence of liver failure and bile cancer associated with PSC

Increasing prevalence of diseases associated with PSC such as liver cancer and inflammatory bowel disease is expected to enhance the therapeutic adoption of efficient drugs to manage the condition, thus driving growth of the primary sclerosing cholangitis market. According to the World Journal of Gastroenterology, 2017, inflammatory bowel disease (IBD) is diagnosed in around 50-80% of the patients with PSC, with ulcerative colitis (UC) comprising around 80-90% of these cases.

Primary Sclerosing Cholangitis Market - Competitive Analysis

Major players operating in the global primary sclerosing cholangitis market include

1. Acorda Therapeutics, Inc.
2. Gilead Sciences, Inc.
3. NGM Biopharmaceuticals, Inc.
4. Intercept Pharmaceuticals, Inc.
5. Dr. Falk Pharma GmbH
6. Allergan Plc.
7. Shire Plc.
8. Durect Corporation
9. Conatus Pharmaceuticals, Inc.
10. Sirnaomics, Inc.
11. Shenzhen HighTide Biopharmaceutical Ltd.

Primary Sclerosing Cholangitis Market - Taxonomy

By Drug: BTT1023, GS-9674, NGM282, OCA, Cenicriviroc, LUM001, DUR928, norUDCA, HTD1801, IDN-7314, STP705
By Region: North America, Latin America, Europe, Asia Pacific, Middle East, Africa

Browse Complete Research Report @ https://bit.ly/2EAyO6n

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at sales@coherentmarketinsights.com

https://www.coherentmarketinsights.com/phase-xs/

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.